Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ciprofloxacin + rifaximin
- Development stage
- Phase 2
- Lead developer
- Salix Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ciprofloxacin + rifaximin is a combination antibiotic therapy primarily used for treating chronic active refractory pouchitis. Ciprofloxacin is a fluoroquinolone antibiotic that treats a wide variety of infections, while rifaximin is a poorly absorbed rifamycin derivative. This combination has shown effectiveness in cases where other treatments have failed, with studies demonstrating significant improvement in patients with chronic active refractory pouchitis when treated with rifaximin 1g twice daily plus ciprofloxacin 500mg twice daily for two weeks.
- Other names
- rifaximin + ciprofloxacinciprofloxacin + rifaximin
02
Targets
Beyond the preview
Go deeper on ciprofloxacin + rifaximin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ciprofloxacin + rifaximin.